about
Pharmacological interventions for the acute management of hyperkalaemia in adultsHyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for managementRecent advances in treatment of heart failureOptimizing haemodialysate compositionCombination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal functionClinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failureStop chronic kidney disease progression: Time is approachingCharacterization of structure and function of ZS-9, a K+ selective ion trapUpdates in hyperkalemia: Outcomes and therapeutic strategies.Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36Advances in treatment of hyperkalemia in chronic kidney disease.Acute hyperkalemia leading to flaccid paralysis: a review of hyperkalemic manifestationsThe Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney DiseaseHypertension Management in Diabetic Kidney DiseaseLong-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients.Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKDPotassium-Binding Agents for the Clinical Management of Hyperkalemia.Potassium and Its Discontents: New Insight, New TreatmentsNovel Bloodless Potassium Determination Using a Signal-Processed Single-Lead ECGMaintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.An electronic alert to decrease Kayexalate ordering.Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.Potential New Agents for the Management of Hyperkalemia.Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.How Dangerous Is Hyperkalemia?A retrospective study of emergency department potassium disturbances: severity, treatment, and outcomes.Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.Renin-angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and a look ahead.Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison.Potassium: friend or foe?New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits.Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure.Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.Managing Hyperkalemia: Stepping Into a New Frontier.
P2860
Q24186355-79B57271-CC47-4000-8A37-2F70DA56E357Q26765228-C4449F15-5B85-47E8-97E6-9B80C5D3B933Q26766223-90ABE576-72ED-416F-850C-2D76D019FC33Q26785879-8A25CD78-18F5-4AD9-9E3E-5F25C6E6036AQ26795398-187C15FB-2A00-49FD-B1ED-C5BDC3FE5037Q26796378-248F037E-10BF-4BA8-825A-CC4128A4CFB9Q28078020-6A364A0A-BA28-4A1A-A783-8443CF3AB402Q28542799-893B62B0-BF36-43F7-8F41-232E63F8E783Q30245585-E21F3B60-A47B-45BB-89A5-3FE87510440DQ30250020-ED03CB46-6328-4995-AC9F-24EBA80C9FE1Q33620311-B00D1FDE-D17C-4352-8057-4573185B135CQ34491934-A535ADF1-9A3C-4357-96FA-4556FB7C5947Q35762203-6D497804-6592-4041-89AB-1B97C0851A78Q35914820-765F7F5D-9120-4F78-AA3F-F28E86A15B69Q35953909-F0234EAE-0725-40B3-8481-19C75244B4DAQ36318268-A120F4D7-50C0-47B7-AF2A-499397D0FA17Q36349441-8B27022E-2496-4275-8743-3C5E954D3F22Q36425315-322A5DF8-FF17-4640-A34A-40D789410AA9Q36746113-0F560171-3558-42B0-B79E-5B0857A3A356Q36877800-B4E13C48-50F6-4471-AEC8-2FD4ADB3DAFEQ37275785-73F39C67-BF0D-465B-876B-2522CD7D2C33Q37420987-25922EC3-680D-4CBC-9312-0C542A7D25F8Q37722892-9DDC4CFE-AFE8-4248-AD88-63E2EB305FB1Q38533385-1CCE2292-BA6B-485C-A22B-B4B2BCD1E181Q38544101-E421FFDE-5DF4-40F3-8D2F-BC9AB887410EQ38566920-8BF1AA27-B9C0-446D-818F-63A6E27DD025Q38639874-F2507663-43DC-449E-9C53-831EB5CACE3EQ38674568-2D2311DB-88B6-47DF-8B74-AB6C69CE435EQ38734501-DB8D0E20-213A-4FE3-AD01-229AADE3B64BQ38766590-3D3098A7-07B7-46E8-AD90-FA44B7422819Q38777543-BBE33750-D45B-4E62-8ADB-34D131A6F540Q38783092-D87E33D3-58C4-4CB3-BE01-5617C840FF94Q38786625-1717F7D5-B0C2-4CD5-B78E-08A331B3FA76Q38806963-2F1E08BA-C5F5-4E32-9CBF-342429DDB4ECQ38838019-7EFBCDFF-C0CB-4777-ACFB-3620E5636BD9Q38845433-C9C080E9-BD3C-45D8-8954-5F646248E02BQ38859432-00749ADC-AE06-45F1-A5DD-3C1463CC1157Q38859478-F07C5C53-1B69-4BD4-A7E4-D3F67C2B6BD3Q38890685-2ACF4668-E194-469F-BC14-36BCD64EDABBQ38949822-BF3F0BA9-F937-4343-9102-22BF9CF10126
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sodium zirconium cyclosilicate in hyperkalemia.
@ast
Sodium zirconium cyclosilicate in hyperkalemia.
@en
Sodium zirconium cyclosilicate in hyperkalemia.
@nl
type
label
Sodium zirconium cyclosilicate in hyperkalemia.
@ast
Sodium zirconium cyclosilicate in hyperkalemia.
@en
Sodium zirconium cyclosilicate in hyperkalemia.
@nl
prefLabel
Sodium zirconium cyclosilicate in hyperkalemia.
@ast
Sodium zirconium cyclosilicate in hyperkalemia.
@en
Sodium zirconium cyclosilicate in hyperkalemia.
@nl
P2093
P356
P1476
Sodium zirconium cyclosilicate in hyperkalemia.
@en
P2093
Bhupinder Singh
David K Packham
Geoffrey Block
Henrik S Rasmussen
Mohamed A El-Shahawy
Pablo Pergola
Philip T Lavin
Simon D Roger
Wajeh Qunibi
P304
P356
10.1056/NEJMOA1411487
P407
P577
2014-11-21T00:00:00Z